share_log

Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts

Benzinga ·  May 14 15:00

6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings33000
Last 30D10000
1M Ago21000
2M Ago01000
3M Ago01000

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $22.00, and a low estimate of $13.00. A decline of 6.67% from the prior average price target is evident in the current average.

price target chart

Deciphering Analyst Ratings: An In-Depth Analysis

The...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment